The study can assure clinicians that Sandoz's Zarxio works just as well in febrile neutropenia as originator Amgen's Neupogen, author says in interview.
On Friday, the Food and Drug Administration approved the first biosimilar, marking an initial big step foward in changing the climate of the drug market in the United States. Time to save some money. Zarxio, produced by Sandoz, Inc. – a division of Novartis, is a drug that is designed to help the body produce […]
By reducing administrative burden and redesigning workflows around human needs, it creates space for what matters most: connection between clinicians and patients.